In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China

You may also be interested in...



Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets

TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity

Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets

TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity

Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States

Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia

Related Content

UsernamePublicRestriction

Register

SC073827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel